三批VSV-EBOV疫苗将被分别装入三个特殊的容器中,容器中盛有干冰,以保证温度在零下80摄氏度(即零下112华氏度)。VSV-EBOV疫苗是在加拿大国家微生物实验室中研发出来的。加政府授权生物技术公司NewLink Genetics Corp生产,希望该疫苗能帮助阻止埃博拉病毒在西非的蔓延。
The vaccine is a combination of a weakened version of the vesicular stomatitis virus, or VSV, found in animals including cattle and horses, and protein from the Ebola virus. VSV is zoonotic, meaning it can be transferred from animals to humans. Infected humans develop flulike symptoms, according to the University of Wisconsin School of Veterinary Medicine. The VSV-EBOV vaccine triggers an immune system response that produces antibodies against the Ebola protein, similar to the way a flu shot works.
VSV-EBOV疫苗是由在牛、马等动物身上提取的水疱性口炎病毒(即VSV)和埃博拉病毒蛋白质组合而成。VSV是一种人畜共患病毒,也就是说它可以在动物和人之间传播。根据威斯康星大学兽医学院的研究,感染VSV的人会表现出流感的症状。VSV-EBOV疫苗能够诱发人体免疫系统产生应对埃博拉病毒蛋白质的抗体,这和流感疫苗的原理类似。
Clinical trials are under way at the Walter Reed Army Institute of Research, headquartered in Silver Spring, Md. Results will not be available until December. Canada has been at the forefront of Ebola drug development, with TKM-EBOLA and ZMapp also being developed in Canada with the help of U.S. funding and partnerships. The latter was recently used on the Spanish nurse Teresa Romero, who contracted the virus Oct. 6. Meanwhile, a second vaccine is also in the works in Canada.
【加拿大埃博拉病毒疫苗送交WHO试验】相关文章:
★ 用白菜制作的美女
★ 加油站偶遇的老人
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15